Patents Examined by Zinna N. Davis
  • Patent number: 8614318
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: December 24, 2013
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, Steven Elmore, Aaron Kunzer, Christopher L. Lynch, William McClellan, Cheol-Min Park, Andrew Petros, Xiaohong Song, Xilu Wang, Noah Tu, Michael Wendt, Alexander R. Shoemaker, Michael J. Mitten
  • Patent number: 7977488
    Abstract: The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R3 and R4 are each a hydrogen atom, or one of R3 and R4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R5 is an alkyl group or a salt thereof.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: July 12, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Kajino, Atsushi Hasuoka, Haruyuki Nishida
  • Patent number: 7973161
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: July 5, 2011
    Assignee: Abbott Laboratories
    Inventors: Milan Bruncko, Hong Ding, Steven Elmore, Aaron Kunzer, Christopher L. Lynch, William McClellan, Cheol-Min Park, Andrew Petros, Xiaohong Song, Xilu Wang, Noah Tu, Michael Wendt, Alexander Shoemaker, Michael Mitten
  • Patent number: 7973060
    Abstract: A compound which is effective for inhibiting Fab I, and a method for treating a bacterial infection.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: July 5, 2011
    Assignee: CrystalGenomics, Inc.
    Inventors: Cheol Min Kim, Dong Gyu Shin, Seonggu Ro, Joong Myung Cho, Young Lan Hyun
  • Patent number: 7960436
    Abstract: This invention provides compounds of formula I where Ar1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR3R4 group is situated ortho to the NHC(?X) group; n=1 or 2; X?O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: June 14, 2011
    Assignee: Valeant Pharmaceuticals International
    Inventors: Huanming Chen, Jean-Michel Vernier
  • Patent number: 7947705
    Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: May 24, 2011
    Assignee: Biotie Therapies GmbH
    Inventors: Norbert Höfgen, Hildegard Kuss, Matthias Olbrich, Ute Egerland, Chris Rundfeldt, Karin Steinike, Rudolf Schindler
  • Patent number: 7943614
    Abstract: A carboxamide compound represented by the formula (I): [wherein Q represents a nitrogen-containing 6-membered aromatic heterocyclic group optionally fused with a benzene ring, two or more ring constitutional atoms of the heterocyclic group are a nitrogen atom, and the heterocyclic group may be substituted with at least one group selected from the group consisting of a C1-C3 alkyl group etc.], and a plant disease controlling agent comprising this as an active ingredient.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: May 17, 2011
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Sadayuki Arimori, Yoshiharu Kinoshita
  • Patent number: 7943638
    Abstract: A carboxamide compound represented by the formula (1): [wherein Q represents a nitrogen-containing 6-membered aromatic heterocyclic group optionally fused with a benzene ring, one of ring constitutional atoms of the heterocyclic group is a nitrogen atom and the heterocyclic group may be substituted with a group selected from the group consisting of a C1-C3 alkyl and the like, R1 represents a C1-C3 alkyl group or the like, R2 represents a hydrogen atom or the like, and R3 represents a hydrogen atom or the like] and a plant disease controlling agent comprising this as an active ingredient.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: May 17, 2011
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Shin-ichiro Souma, Yoshiharu Kinoshita
  • Patent number: 7939548
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: May 10, 2011
    Assignee: Cytokinetics, Inc.
    Inventors: Pu-Ping Lu, Xiangping Qian, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans, Jr.
  • Patent number: 7939549
    Abstract: The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 10, 2011
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Satoshi Nagato, Kohshi Ueno, Koki Kawano, Yoshihiko Norimine, Koichi Ito
  • Patent number: 7939534
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: May 10, 2011
    Assignee: Cytokinetics, Inc.
    Inventors: Pu-Ping Lu, Xiangping Qian, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans, Jr.
  • Patent number: 7932270
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: April 26, 2011
    Assignee: Cytokinetics, Inc.
    Inventors: Pu-Ping Lu, Xiangping Qian, Jeffrey T. Finer, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans, Jr.
  • Patent number: 7932266
    Abstract: The invention relates to derivative compounds of partially-reduced isoquinoline with substitution of a sec-butyl group at position 3 with calpain inhibitor activity. The inventive compound comprises an ester or amide derived from (3-sec-butyl-1-oxo-2,3-dihydro-1H-isoquinolin-4-yliden)-acetic acid and (3-sec-butyl-1-thioxo-2, 3-dihydro-1H-isoquinolin-4-yliden)-acetic acid. Compounds having formula I or II can be used in the preventive or therapeutic treatment of a degenerative disease.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: April 26, 2011
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Bernardo Herradon García, Roberto Chicharro Martin, Vicente Jesús Aran Redo, Mercedes Alonso Giner
  • Patent number: 7928123
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: April 19, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Angela Berry, Pier Francesco Cirillo, Doris Riether, David Thomson, Renee M. Zindell, Nigel Blumire, Chandana Chowdhury, Monika Ermann, James Edward Jenkins, Innocent Mushi, Christopher Francis Palmer, Malcolm Taylor
  • Patent number: 7928121
    Abstract: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: April 19, 2011
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Antoni Torrens Jover, Susana Yenes Mínguez, Josep Mas Prió, Luz Romero Alonso, Alberto Dordal Zueras, Helmut Henrich Buschmann
  • Patent number: 7923446
    Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: April 12, 2011
    Assignee: Wyeth LLC
    Inventors: Jason Shaoyun Xiang, Steve Yikkai Tam, Yonghan Hu, Phaik-Eng Sum, David Brian How, Darrin William Hopper, Matthew Douglas Vera, Joshua James Sabatini, Thomas Saltmarsh Rush, III, Elisabeth Ann Morris, Katy Evangelia Georgiadis
  • Patent number: 7923461
    Abstract: A compound having the following formula wherein A is —O—; B is alkylene or alkenylene optionally containing —O—, —S—, —(NR7)—, —CO— or —N?; R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl is unsubstituted or substituted by halogen, cycloalkyl, aryl, adamantyl or amino; R3 is a substituted or unsubstituted pyridine ring; R5 and R6 are hydrogen or alkyl; R7 is hydrogen or alkyl; X is O or S; and each hydrogen of the said amino is unsubstituted or substituted by alkyl, alkoxycarbonyl, cycloalkyloxycarbonyl, arylalkoxycarbonyl or halogenoalkyloxycarbonyl. The compound is a TNF-? production inhibitor that is useful for treating autoimmune diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: April 12, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
  • Patent number: 7919511
    Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: April 5, 2011
    Assignee: Cytokinetics, Inc.
    Inventors: Pu-Ping Lu, Xiangping Qian, Jeffrey T. Finer, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans, Jr.
  • Patent number: 7919504
    Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: April 5, 2011
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Chester Chenguang Yuan, Guomin Yao, Xianghong Wang, Seifu Tadesse, Andreas Reichelt, Qingyian Liu, Matthew R. Lee, Xin Huang, Fang-Tsao Hong, Nianhe Han, Christopher H. Fotsch, Celia Dominguez, Matthew P. Bourbeau, John G. Allen
  • Patent number: 7915263
    Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R1? is a hydrogen atom or lower alkyl which may be substituted; R2 is O, S, SO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: March 29, 2011
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Yoshikazu Iwasawa, Tetsuya Kato, Nobuhiko Kawanishi, Kouta Masutani, Takashi Mita, Katsumasa Nonoshita, Mitsuru Ohkubo